PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10904979

[Current data on gabapentin].

J L Herranz
View original source ↗Export metadata ↓

Abstract

OBJECTIVE: To review the current data on gabapentin (GBP) with regard to its mechanism of action, pharmacokinetic characteristics, clinical efficacy, tolerance and mode of administration. DEVELOPMENT: GBP has a multiple mechanism of action which justifies its use in many clinical conditions besides epilepsy. These include neuropathic pain, psychiatric disorders, disorders of movement, and migraine. Its pharmacokinetic characteristics are nearly those of an ideal drug, with no interactions. Regarding clinical efficacy, there is much evidence of this in polytherapy and in monotherapy in adults and children with partial crises, with rare adverse effects and the exceptional possibility to establish the total dose of GBP in only a few days. CONCLUSIONS: GBP is an effective drug in patients of all ages with partial crises. Because of its excellent tolerance and decreasing dose-dependent kinetics, conditioned by less absorption of the drug, we recommend the administration of GBP at doses higher than those normally used. Thus we suggest a dose of 900 to 2,400 mg/day in patients with a new diagnosis, of 1,800 to 3,600 mg/day as a second therapeutic alternative and even 2,400 to 4,800 mg/day when other antiepileptic drugs have failed to be of use.

Explore related subjects

AcetatesAdultAminesAnticonvulsantsChildChild, PreschoolCyclohexanecarboxylic AcidsDrug Administration ScheduleDrug ToleranceEpilepsyGabapentinHumansTreatment Outcomegamma-Aminobutyric AcidJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J L Herranz. 2000. [Current data on gabapentin].. https://pubmed.ncbi.nlm.nih.gov/10904979/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2002

Probing a pheromone binding protein of the silkmoth Antheraea polyphemus by endogenous tryptophan fluorescence.

One subtype of the pheromone binding proteins of the silkmoth Antheraea polyphemus (ApolPBP1) has been analysed exploiting the two endogenous tryptophan residues as fluorescent probe. The intrinsic fluorescence exhibited a rather narrow spectrum with a maximum at 336 nm. Site-directed mutagenesis experiments revealed that one of the tryptophan residues (Trp37) is located in a hydrophobic environment whereas Trp127 is more solvent exposed, as was predicted modeling the ApolPBP1 sequence on the proposed structure of the Bombyx mori pheromone binding protein. Monitoring the interaction of ApolPBP1 as well as its Trp mutants with the three species-specific pheromone compounds by recording the endogenous fluorescence emission revealed profound differences; whereas (E6,Z11)-hexadecadienal induced a dose-dependent quenching of the fluorescence, both (E6,Z11)-hexadecadienyl-1-acetate and (E4,Z9)-tetradecadienyl-1-acetate elicited an augmentation of the endogenous fluorescence. These data indicate that although ApolPBP1 can bind all three pheromones, there are substantial differences concerning their interaction with the protein, which may have important functional implications.

Acetates↗
PubMed2002

Palladium-catalyzed arylation of malonates and cyanoesters using sterically hindered trialkyl- and ferrocenyldialkylphosphine ligands.

Palladium-catalyzed reactions of aryl bromides and chlorides with two common stabilized carbanions-enolates of dialkyl malonates and alkyl cyanoesters-are reported. An exploration of the scope of these reactions was conducted, and the processes were shown to occur in a general fashion. Using P(t-Bu)(3) (1), the pentaphenylferrocenyl ligand (Ph(5)C(5))Fe(C(5)H(4))P(t-Bu)(2) (2), or the adamantyl ligand (1-Ad)P(t-Bu)(2) (3), reactions of electron-poor and electron-rich, sterically hindered and unhindered aryl bromides and chlorides were shown to react with diethyl malonate, di-tert-butyl malonate, diethyl fluoromalonate, ethyl cyanoacetate, and ethyl phenylcyanoacetate. Although alkyl malonates and ethyl alkylcyanoacetates did not react with aryl halides using these catalysts, the same products were formed conveniently in one pot from diethylmalonate by cross-coupling of an aryl halide in the presence of excess base and subsequent alkylation.

Acetates↗
PubMed2002

Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes.

BACKGROUND: Platelet glycoprotein IIb/IIIa inhibitors reduce the rate of death or myocardial infarction among patients with acute coronary syndromes without persistent ST-segment elevation, but their effects may depend on plasma concentrations. We tested whether the addition of lamifiban, titrated to achieve target plasma concentrations, to standard care would improve clinical outcomes. METHODS AND RESULTS: We randomized 5225 patients at 389 centers in 29 countries to receive a bolus and </=72-hour infusion of lamifiban or placebo, adjusted for renal function, with aspirin and heparin. The primary end point was the composite of death, myocardial infarction, or severe, recurrent ischemia at 30 days. Baseline characteristics did not differ significantly by treatment. The primary end point occurred in 11.8% of lamifiban-treated patients and in 12.8% of placebo-treated patients (OR, 0.914; 95% CI, 0.769 to 1.087; P=0.329). Bleeding was more common in lamifiban-treated patients, but intracranial hemorrhage was not increased. Among the subgroup who had plasma lamifiban concentrations measured, 91% had a concentration >18 ng/mL at steady state, but their outcomes did not differ from those with lower concentrations. CONCLUSIONS: Lamifiban showed no significant effects on clinical outcomes in patients with non-ST-elevation acute coronary syndromes, despite achievement of adequate plasma concentrations.

Acetates↗